Hemostemix Inc. (CVE:HEM – Get Free Report) was up 23.1% during mid-day trading on Thursday . The company traded as high as C$0.08 and last traded at C$0.08. Approximately 202,500 shares changed hands during trading, an increase of 99% from the average daily volume of 101,718 shares. The stock had previously closed at C$0.07.
Hemostemix Trading Up 12.5 %
The company’s 50 day simple moving average is C$0.07 and its 200 day simple moving average is C$0.06. The stock has a market capitalization of C$7.84 million, a PE ratio of -4.50 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Investing in Commodities: What Are They? How to Invest in Them
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Basic Materials Stocks Investing
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- The Basics of Support and Resistance
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
